MSD
MSD scores EU approval for Keytruda in lung cancer
August 3, 2016Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer
MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …
400 current and former employees join sexual discrimination lawsuit against MSD
July 25, 2016Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit
Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …
MSD faces delay in C. diff drug approval as FDA requests more data
July 22, 2016Medical Communications, Research and Development C diff, FDA, MSD, Merck
MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …
UK medical charity sells part of interest in MSD’s Keytruda for $150 million
July 15, 2016Research and Development, Sales and Marketing MSD, Merck, keytruda
UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …
MSD gets CHMP positive opinion for keytruda to treat advanced lung cancer
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing CHMP, EMA, MSD, Merck & Co, keytruda, lung cancer
MSD (Merck & Co) said its anti-programmed death-1 (PD-1) therapy, Keytruda (pembrolizumab) to treat lung cancer has secured a positive …
Merck & Co says Keytruda shows better results than chemotherapy in Phase III trials for lung cancer
June 17, 2016Medical Communications MSD, Merck & Co, drug trial, keytruda, lung cancer
US drug major Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced non-small-cell …
MSD insulin glargine biosimilar meets primary endpoint in late-stage trials
June 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Merck, biosimilar, insulin, insuline glargine
MSD (NYSE: MRK), known as Merck in the US and Canada, has announced results from two Phase III studies evaluating …
FDA committee recommends MSD’s c. diff prevention drug
June 10, 2016Medical Communications, Research and Development, Sales and Marketing FDA, MSD, Merck, bezlotoxumab, committee, zinplava
The US Food and Drug Administration’s (FDA) antimicrobial drugs advisory committee has voted by 10 to 5, with one abstention, …
MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival
June 8, 2016Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda
Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …
MSD to collaborate with Fujifilm Diosynth on new microbial biologics facility
June 7, 2016Manufacturing and Production, Research and Development MSD, Merck, fujifilm diosynth
MSD, known as Merck in the US and Canada, has entered into a collaboration with Fujifilm Diosynth Biotechnologies to invest …
Judge reverses verdict in MSD/Gilead hepatitis C dispute
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi
A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …
Trial data shows promise for Lilly/MSD combo regimen in lung cancer
June 6, 2016Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship
Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …
MSD receives fourth Breakthrough Therapy Designation for Keytruda
April 19, 2016Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …
FDA accepts biologics license application for MSD’s allergy immunotherapy drug
April 13, 2016Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …
Gilead must pay MSD $200m in hep C drug patent case
March 29, 2016Manufacturing and Production, Sales and Marketing Gilead Sciences, MSD, Solvadi, harvoni
A Californian federal jury has ordered Gilead Sciences to pay MSD and Ionis $200 million for infringing on patents relating …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
